- Home
- KZIA vs MOLN Comparison
KZIA vs MOLN Comparison
Compare KZIA & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KZIA | MOLN |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | Australia | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 154.2M |
| IPO Year | 2002 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KZIA | MOLN |
|---|---|---|
| Price | $12.35 | $3.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $19.50 | $8.38 |
| AVG Volume (30 Days) | ★ 163.3K | 6.5K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.86 | $3.41 |
| 52 Week High | $17.40 | $5.36 |
Technical Indicators
Market Signals| Indicator | KZIA | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 47.76 |
| Support Level | $11.90 | $3.64 |
| Resistance Level | $14.75 | $3.96 |
| Average True Range (ATR) | 1.07 | 0.09 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 10.77 | 44.00 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.